🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Epidemiology of Carbapenemase-producing Bacteria in a Swiss Tertiary Care Hospital

Recruitingn/aAges 18 Years - anyAllUniversity Hospital, Basel, Switzerland
NCT04098133 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This retrospective and prospective study is to investigate the incidence of Carbapenemase-producing bacteria (CPB) at the University Hospital Basel, the time to detection of CPB and to initiation of infection control measures, the risk factors associated with carriage of CPB, type and duration of previously administrated antibiotic medication, antibiotic treatment, as well as to assess the outcomes of the affected patients.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with detection of carbapenemase-producing bacteria from January 1st , 2008 until December 31st , 2028 Exclusion Criteria: * Patients with documented refusal of subsequent use of their data
💊

What it tests

  • data collection for demographic data
  • data collection for clinical data
  • data collection for treatment data
  • data collection for microbiological data
📍

Where

1 site
Division of Infectious Diseases and Hospital Epidemiology
Basel, Switzerland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy